Informations

The 2024 European Society for Medical Oncology (ESMO) Congress took place in Barcelona, Spain, from September 13 to 17. During the event, Dr. Miaoyan Wei from Fudan University Shanghai Cancer Center presented the results of an open-label, single-arm, single-center Phase II clinical trial exploring the use of fruquintinib combined with nab-paclitaxel and gemcitabine (AG) as…

The 2024 World Conference on Lung Cancer (WCLC), hosted by the International Association for the Study of Lung Cancer (IASLC), is currently in full swing in San Diego, USA.  Oncology Frontier invited domestic lung cancer experts to analyze key research data from the conference. This article presents Dr. Shengxiang Ren’s review of the NeoCOAST-2 study…

The 2024 European Society for Medical Oncology (ESMO) Annual Congress was held from September 13 to 17 in Barcelona, Spain, where multiple advancements in lung cancer research were presented. Dr. Jonathan D. Spicer from the McGill University Health Centre in Montreal, Canada, shared the updated clinical data from the CheckMate 77T study. During the congress,…

The 2024 World Conference on Lung Cancer (WCLC) recently concluded in San Diego, USA. As one of the largest academic conferences in the field of oncology, WCLC presents the latest cutting-edge advancements, covering all aspects of lung cancer research. Dr. Yilong Wu from Guangdong Provincial People’s Hospital served as an expert chair and delivered a…

A patient-level analysis of the phase III CheckMate 77T trial (NCT04025879) and the phase III CheckMate 816 trial (NCT02998528) revealed that perioperative treatment with nivolumab for resectable non-small cell lung cancer (NSCLC) patients reduces the risk of disease recurrence or death by approximately 40%, compared to neoadjuvant nivolumab plus chemotherapy alone. This article presents Dr.…

EGFR P-loop-aC helix compression (PACC) mutation is a recently identified subtype of EGFR mutations in non-small cell lung cancer (NSCLC), and its potential for precision therapy had not been clinically validated until now. At the 2024 World Conference on Lung Cancer (WCLC 2024), during the Presidential Symposium Presentation, the global phase Ib FURTHER trial’s proof-of-concept…

The 2024 World Conference on Lung Cancer (WCLC), taking place from September 7-10 in San Diego, USA, will showcase key findings from Chinese researchers, including a phase III randomized controlled trial comparing plinabulin plus docetaxel versus docetaxel alone for the treatment of advanced non-small cell lung cancer (NSCLC) after progression on platinum-based chemotherapy. The results…

During the second Presidential Symposium at the 2024 World Conference on Lung Cancer (WCLC), Professor Jing-Ji Yang from Guangdong Provincial People’s Hospital presented the report “Osimertinib with or without Savolitinib as First-Line Treatment for De Novo MET Aberrant, EGFRm Advanced Non-Small Cell Lung Cancer (NSCLC) (CTONG 2008): Results from the Phase II FLOWERS Clinical Trial.”